BIOVICA INTERNATIONAL AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.365 SEK | +3.05% |
|
-4.64% | -8.33% |
| Jun. 28 | Biovica to Provide Biomarker Testing for US Biopharmaceutical Company | MT |
| Jun. 28 | Biovica International Signs New Agreement Supporting Pharma Development | CI |
Valuation
| Fiscal Period: April | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 369.2 | 1,157 | 905.9 | 331.2 | 134 | 198.8 | - | - |
| Enterprise Value (EV) 1 | 328.4 | 1,012 | 829.4 | 331.2 | 134 | 139.8 | 160.1 | 130.8 |
| P/E ratio | -12 x | -29.3 x | -15.1 x | -2.28 x | -0.74 x | -3.38 x | -5.73 x | 10.5 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 221 x | 557 x | 443 x | 97.9 x | 18.4 x | 4.73 x | 1.42 x | 0.86 x |
| EV / Revenue | 197 x | 487 x | 406 x | 97.9 x | 18.4 x | 3.33 x | 1.14 x | 0.56 x |
| EV / EBITDA | -12.8 x | -29.7 x | -15.5 x | -3.24 x | -1.14 x | -2.15 x | -9.97 x | 3.76 x |
| EV / FCF | -10.3 x | -26.7 x | -15 x | - | - | -2.12 x | 22.9 x | 2.84 x |
| FCF Yield | -9.69% | -3.75% | -6.65% | - | - | -47.2% | 4.37% | 35.2% |
| Price to Book | - | 6.33 x | 7.29 x | - | - | 3.23 x | 7.4 x | 6.4 x |
| Nbr of stocks (in thousands) | 23,817 | 28,418 | 28,488 | 45,741 | 84,056 | 84,056 | - | - |
| Reference price 2 | 15.50 | 40.70 | 31.80 | 7.240 | 1.594 | 2.365 | 2.365 | 2.365 |
| Announcement Date | 6/5/20 | 6/17/21 | 6/16/22 | 6/21/23 | 6/18/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: April | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.671 | 2.077 | 2.045 | 3.383 | 7.29 | 42 | 140 | 232 |
| EBITDA 1 | -25.65 | -34.04 | -53.66 | -102.2 | -117.4 | -65 | -16.06 | 34.79 |
| EBIT 1 | -29.82 | -40.18 | -60.1 | -110.5 | -126.8 | -75 | -25.75 | 25.09 |
| Operating Margin | -1,784.32% | -1,934.57% | -2,938.92% | -3,265.06% | -1,739.99% | -178.57% | -18.4% | 10.81% |
| Earnings before Tax (EBT) 1 | -30.26 | -39.39 | -59.99 | -110.7 | -124.1 | -75 | -23.94 | 29.21 |
| Net income 1 | -30.32 | -39.48 | -60 | -110.5 | -124.8 | -70 | -41.88 | 25.02 |
| Net margin | -1,814.36% | -1,900.91% | -2,934.13% | -3,266.1% | -1,712.25% | -166.67% | -29.92% | 10.78% |
| EPS 2 | -1.290 | -1.390 | -2.110 | -3.180 | -2.140 | -0.7000 | -0.4128 | 0.2248 |
| Free Cash Flow 1 | -31.82 | -37.97 | -55.12 | - | - | -66 | 7 | 46 |
| FCF margin | -1,903.95% | -1,828.07% | -2,695.21% | - | - | -157.14% | 5% | 19.83% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 132.24% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 183.85% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 6/5/20 | 6/17/21 | 6/16/22 | 6/21/23 | 6/18/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: April | 2022 Q3 | 2022 Q4 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales | - | 1.082 | - | - | 0.587 | 1.754 | 2.563 | 1.075 | 1.899 | - | - | - | - |
| EBITDA 1 | -12.89 | -17.32 | - | -27.24 | -35.2 | -29.84 | -22.92 | -25.53 | -39.12 | -17 | -17 | -17 | -13 |
| EBIT 1 | -14.42 | -19.13 | - | -29.28 | -37.21 | -32.19 | -25.32 | -27.85 | -41.49 | -19 | -19 | -19 | -16 |
| Operating Margin | - | -1,768.21% | - | - | -6,338.67% | -1,835.35% | -987.75% | -2,590.51% | -2,184.83% | - | - | - | - |
| Earnings before Tax (EBT) 1 | -14.33 | -19.07 | - | -29.18 | -37.2 | -31.94 | -23.77 | -27.58 | -40.83 | -18.63 | -18.53 | -18.92 | -14.94 |
| Net income 1 | -14.33 | -19.06 | -23.25 | -28.54 | -37.7 | -32.26 | -25.68 | -27.34 | -39.53 | -18.63 | -18.53 | -18.92 | -14.94 |
| Net margin | - | -1,761.18% | - | - | -6,422.49% | -1,839.45% | -1,002.11% | -2,543.53% | -2,081.73% | - | - | - | - |
| EPS 2 | -0.5000 | -0.6700 | -0.8100 | -0.6400 | -0.8100 | -0.7000 | -0.5600 | -0.4400 | -0.4700 | -0.2216 | -0.1997 | -0.1865 | -0.1472 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/15/22 | 6/16/22 | 12/15/22 | 3/16/23 | 6/21/23 | 9/6/23 | 11/28/23 | 3/14/24 | 6/18/24 | - | - | - | - |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: April | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 40.8 | 144 | 76.5 | - | - | 59 | 38.7 | 68 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -31.8 | -38 | -55.1 | - | - | -66 | 7 | 46 |
| ROE (net income / shareholders' equity) | - | -30.3% | -39.1% | - | - | -77% | - | 28.7% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 6.430 | 4.360 | - | - | 0.7300 | 0.3200 | 0.3700 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 7.04 | 3.56 | 2.99 | - | - | 1 | 1 | - |
| Capex / Sales | 421.01% | 171.4% | 146.31% | - | - | 2.38% | 0.71% | - |
| Announcement Date | 6/5/20 | 6/17/21 | 6/16/22 | 6/21/23 | 6/18/24 | - | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.365
SEK
Average target price
7.9
SEK
Spread / Average Target
+234.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.33% | 18.88M | |
| -37.33% | 8.55B | |
| +14.86% | 3.8B | |
| +7.38% | 2.44B | |
| -25.96% | 1.87B | |
| -17.30% | 1.74B | |
| +36.49% | 1.19B | |
| +32.58% | 830M | |
| -7.64% | 711M | |
| -18.37% | 589M |
- Stock Market
- Equities
- BIOVIC B Stock
- Financials Biovica International AB
